Edition:
United States

Pacira Pharmaceuticals Inc (PCRX.O)

PCRX.O on Nasdaq

33.10USD
19 Oct 2017
Change (% chg)

$0.05 (+0.15%)
Prev Close
$33.05
Open
$33.00
Day's High
$33.40
Day's Low
$32.65
Volume
473,594
Avg. Vol
663,233
52-wk High
$58.95
52-wk Low
$29.95

Latest Key Developments (Source: Significant Developments)

Pacira Pharmaceuticals announces FDA acceptance of SNDA
Wednesday, 18 Oct 2017 07:30am EDT 

Oct 18 (Reuters) - Pacira Pharmaceuticals Inc :Pacira Pharmaceuticals announces FDA acceptance of SNDA for exparel as a nerve block to produce regional analgesia.Pacira Pharmaceuticals Inc - ‍expected action date by FDA under Prescription Drug User Fee Act (PDUFA) is April 6, 2018​.  Full Article

‍Point72 Asset Management LP reports a 5 pct passive stake in Pacira Pharmaceuticals ​
Tuesday, 22 Aug 2017 04:25pm EDT 

Aug 22 (Reuters) - Pacira Pharmaceuticals Inc :‍Point72 Asset Management LP reports a 5.0 pct passive stake in Pacira Pharmaceuticals Inc as of Aug 21 - SEC filing ​.  Full Article

Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals
Monday, 14 Aug 2017 06:34am EDT 

Aug 14 (Reuters) - Pacira Pharmaceuticals Inc :Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals, as of Aug 3 - SEC filing ​.  Full Article

Pacira Pharmaceuticals reports Q2 GAAP loss per share of $0.49
Wednesday, 2 Aug 2017 07:30am EDT 

Aug 2 (Reuters) - Pacira Pharmaceuticals Inc ::Pacira pharmaceuticals, inc. Reports second quarter 2017 financial results.Q2 non-GAAP loss per share $0.11.Q2 GAAP loss per share $0.49.Q2 revenue $70.9 million versus I/B/E/S view $73.4 million.Q2 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S.Pacira pharmaceuticals inc says full-year exparel net product sales guidance of $290 to $310 million reiterated.  Full Article

Pacira announces topline phase 3 results for Exparel
Tuesday, 25 Jul 2017 07:30am EDT 

July 25 (Reuters) - Pacira Pharmaceuticals Inc :Pacira announces topline phase 3 results for Exparel as a single-dose nerve block.‍Lower extremity study defined safety and pharmacokinetic profile through 120 hours​.‍Timing for resubmission of supplemental new drug application remains on track​.‍Upper extremity study showed that Exparel significantly reduces pain scores and opioid use​.  Full Article

Pacira Pharma says President James Scibetta has resigned
Tuesday, 23 May 2017 04:30pm EDT 

May 23 (Reuters) - Pacira Pharmaceuticals Inc :Pacira pharmaceuticals -james scibetta resigning as president to become ceo of an undisclosed private early-stage oncology company.Pacira pharmaceuticals -will allocate scibetta's operational oversight responsibilities to current leadership team, does not intend to name successor.  Full Article

Pacira Pharmaceuticals Inc reports Q1 GAAP loss per share $0.52
Thursday, 4 May 2017 08:00am EDT 

May 4 (Reuters) - Pacira Pharmaceuticals Inc ::Pacira pharmaceuticals, inc. Reports first quarter 2017 financial results.Q1 non-GAAP loss per share $0.19.Q1 GAAP loss per share $0.52.Q1 revenue $69.3 million versus I/B/E/S view $70.3 million.Q1 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S.Says reaffirms FY 2017 exparel net product sales guidance of $290 million to $310 million.  Full Article

Christopher James reports a 5.9 pct passive stake in Pacira Pharmaceuticals
Monday, 17 Apr 2017 06:02am EDT 

April 17 (Reuters) - Pacira Pharmaceuticals Inc :Christopher James reports a 5.9 percent passive stake in Pacira Pharmaceuticals as of April 4, 2017 - SEC filing.  Full Article

Trinity and Pacira announce collaboration to decrease opioid use nationwide
Thursday, 16 Mar 2017 07:30am EDT 

Pacira Pharmaceuticals Inc : Trinity Health and Pacira Pharmaceuticals announce collaboration to decrease opioid use nationwide .Co, Pacira Pharmaceuticals announced they will collaborate to develop an alternative approach to opioids for pain management.  Full Article

Pacira Pharmaceuticals announces proposed offering of $300 million aggregate principal amount of convertible senior notes
Monday, 6 Mar 2017 04:01pm EST 

Pacira Pharmaceuticals Inc : Announces proposed offering of $300 million aggregate principal amount of convertible senior notes . Announced it intends to offer $300 million aggregate principal amount of convertible senior notes due 2022 .Intends to use portion of net proceeds to enter into agreements with certain holders of 3.25 pct convertible senior notes due 2019.  Full Article

BRIEF-Pacira Pharmaceuticals announces FDA acceptance of SNDA

* Pacira Pharmaceuticals announces FDA acceptance of SNDA for exparel as a nerve block to produce regional analgesia